Treatment options and outcomes for glioblastoma in the elderly patient - Wikidata - wikimedia - TriplyDB

Treatment options and outcomes for glioblastoma in the elderly patient

Treatment options and outcomes for glioblastoma in the elderly patient

http://www.wikidata.org/entity/Q26991605

about

A Surveillance, Epidemiology and End Results-Medicare data analysis of elderly patients with glioblastoma multiforme: Treatment patterns, outcomes and cost Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database Model averaged double robust estimation.Medical therapy of gliomas.The clinico-oncologic outcomes of elderly patients with glioblastoma after surgical resection followed by concomitant chemo-radiotherapy Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma.Infarct volume after glioblastoma surgery as an independent prognostic factor.Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score-matching analysis.Glioblastoma in the elderly: treatment patterns and survival.Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.TGF-â1-induced miR-503 controls cell growth and apoptosis by targeting PDCD4 in glioblastoma cells.EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco.Recent advances in cancer surgery in older patients.MiR-10b decreases sensitivity of glioblastoma cells to radiation by targeting AKT.Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: A National Cancer Database Analysis.Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma.Optimal Therapies for Newly Diagnosed Elderly Patients with Glioblastoma.Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume.Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells.Glioblastoma in Patients over 70 Years of Age

P2860

Q31029542-19F780B5-D9C6-4020-A2B7-67BD5DFA2827 Q33775341-AE33ED11-EDB1-41B5-AE61-6D22392D4776 Q33785407-4168D0F2-F5B4-4EC2-B9CC-F863F916F584 Q34218761-99BDEDC0-4749-454B-9946-BAFE7DD4D9C4 Q34509456-89411AB1-7E4E-45BE-AA02-40D0E63BDDA8 Q37237358-EE96D795-4B6D-4E7D-83EB-8EE9704F78C4 Q37641715-656EF5A8-B871-4278-A423-DB53A50440A7 Q38598949-52B01D00-5F87-4F11-9940-1FC18821111A Q39045945-CF241D23-806E-4C58-BCD2-0E71B3C2A9D8 Q40095195-D1A6A7D3-B2F2-470C-8882-5C3BDC2F1544 Q41048323-F5B84B54-9D8E-41A5-99F5-52AE92B1B64B Q41146626-93FA8CEC-7A86-4E5B-A973-4FAF52EBB538 Q42338971-AF5AF8F9-4BB7-42A6-8313-FC27EAF9FFC7 Q42534830-19A8AE58-AE77-41ED-A8CC-1034512DE7D8 Q45298561-FDFE5DE4-D755-4F78-AEA6-141A97996AC4 Q45868285-ACC42011-C8D4-4905-8192-E5D46C831E2F Q47361207-32BE0A64-84C9-4073-8482-260897A0049C Q47627726-894AA4E1-8658-4196-A1B4-D81AB88AD31D Q47916539-DF7BE2C2-41D7-4740-BB5B-C017AB8E257F Q47996641-5AD16222-CB8E-4357-909E-BB8A65AC8CF2 Q48163068-BE298468-EB28-46F4-B7E0-E07062398386 Q52652673-0857EEAC-FDAB-4EC3-871D-824CE7A6BDEE Q57107063-DD41DF01-D082-404E-95B6-194B7841D018

P2860

Treatment options and outcomes for glioblastoma in the elderly patient

http://www.wikidata.org/entity/Q26991605

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Treatment options and outcomes for glioblastoma in the elderly patient

@ast

Treatment options and outcomes for glioblastoma in the elderly patient

@en

Treatment options and outcomes for glioblastoma in the elderly patient

@nl

type

label

Treatment options and outcomes for glioblastoma in the elderly patient

@ast

Treatment options and outcomes for glioblastoma in the elderly patient

@en

Treatment options and outcomes for glioblastoma in the elderly patient

@nl

prefLabel

Treatment options and outcomes for glioblastoma in the elderly patient

@ast

Treatment options and outcomes for glioblastoma in the elderly patient

@en

Treatment options and outcomes for glioblastoma in the elderly patient

@nl

P1433

Q26991605-D4F0EF8B-3909-4E21-BFFB-5EE3C7119A09

P1476

Q26991605-94649A75-C724-4DF2-89DE-405CBEBFCFE0

P2093

Q26991605-E30A6BEB-1F14-4EAB-AD6D-C759BF8E458C

P275

Q26991605-7A3A5BBB-8A5E-4B26-8287-58D4E2AE6DE0

P2860

Q26991605-10B0EFB3-63AF-4EE8-A9A1-41EFD0A40870

Q26991605-1D6E35C3-CE2E-4C87-A6A6-55C43E198AAB

Q26991605-1DAE26FE-7A2E-4D49-9B79-91809D919A2F

Q26991605-20AB4AB3-FC22-418E-9797-FB01F888F900

Q26991605-28ABA771-D135-4E42-8E18-BED4C9BFBA3D

Q26991605-2CD09D61-C135-4C58-90B2-04C51C68A830

Q26991605-3412579C-B5F9-4299-8B5F-62B781713A39

Q26991605-34E0BCBB-3EC0-410A-A9D2-961E9D47755B

Q26991605-3C2F4E61-1C9F-4BEE-BBC7-E16C02C8248D

Q26991605-3D0B4023-2933-4925-828C-E824B606217E

P304

Q26991605-663B50AC-C812-4842-8767-DD549C13A38E

P31

Q26991605-053946B7-8E6A-4F45-BC47-4BF4E76438A7

Q26991605-A1C2E14D-088A-4A29-A159-125764E193C4

P3181

Q26991605-51B83126-9FF1-4918-831A-829911096799

P356

Q26991605-F0777478-5F5D-4A9C-BBA1-CC45E10E0EB2

P407

Q26991605-93089BB6-2F6D-445A-98B7-9E66051253C0

P478

Q26991605-62EC5FE8-2F31-4F72-8EC0-5873DC31C739

P50

Q26991605-7E44CB63-069D-49F8-A963-EBA899D72C9C

P5008

Q26991605-1B68F1BC-8303-4049-9076-FA6769D65056

P577

Q26991605-39735AC4-27AA-4569-9E51-5BB5DBBF937C

Q26991605-A98D548F-FBED-4E1D-89A5-1FD268FE9F66

P5875

Q26991605-80C4FF70-B4E4-4637-910D-97FBB1473A72

P698

Q26991605-A6AB8135-C5C1-4074-8C27-A6848ED210C9

P921

Q26991605-59C86A4C-6D7F-4442-89ED-554DD772031C

Q26991605-91C78598-2231-4848-B7DF-7F589EE5C002

Q26991605-D30202CC-D518-4F96-B8C2-0DD51FE13C8A

P932

Q26991605-FE592863-365C-40D7-9DA8-E6069F03E9FB

P3181

P356

P1433

Clinical Interventions in Aging

P1476

Treatment options and outcomes for glioblastoma in the elderly patient

@en

P2093

Nils Arvold

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

IDH1 and IDH2 mutations in gliomas

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.

Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

P304

357-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

492484

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/CIA.S44259

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

David A Reardon

P5008

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260486805

http://www.w3.org/2001/XMLSchema#string

P698

24591820

http://www.w3.org/2001/XMLSchema#string

P921

P932

3937103

http://www.w3.org/2001/XMLSchema#string